Literature DB >> 19583489

Anaplastic thyroid carcinoma in a young woman: a rare case of survival.

Ariana Pichardo-Lowden1, Saima Durvesh, Svetlana Douglas, William Todd, Michael Bruno, David Goldenberg.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is rare but one of the most aggressive human cancers. It carries a dismal prognosis with average survival of 6 months. It is characteristically diagnosed in patients older than 60 years. We report the case of a young patient with ATC, in whom disease-free survival exceeds 2 years, and review the related literature.
SUMMARY: A 26-year-old woman presented with a rapidly growing anterior neck mass. A neck computed tomography scan showed a 3.5-cm left thyroid mass extending into the lateral neck. Fine-needle aspiration biopsy showed a malignant tumor. A subsequent core biopsy showed an undifferentiated epithelial carcinoma. A total thyroidectomy and left modified radical neck dissection were performed. Histopathology and immunohistochemical analysis confirmed an ATC. Postoperatively, the patient received radiation with concurrent chemotherapy. Serial follow-up imaging studies showed no evidence of residual or recurrent disease or metastases, and patient remains alive, free of disease, over 2 years.
CONCLUSION: ATC is usually a disease of the elderly but should be considered in the differential diagnosis of any patient who presents with a rapidly enlarging anterior neck mass. A rapid and thorough investigation should be initiated. This unusual case highlights that this aggressive thyroid cancer may occur in the young. It also emphasizes the role of aggressive surgery, if resectable.

Entities:  

Mesh:

Year:  2009        PMID: 19583489     DOI: 10.1089/thy.2009.0025

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  Dyspnea as a prognostic factor in anaplastic thyroid carcinoma.

Authors:  Lauren Tashima; Ron Mitzner; Saima Durvesh; David Goldenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-20       Impact factor: 2.503

2.  Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

Authors:  Xiaoguang Shi; Rengyun Liu; Shen Qu; Guangwu Zhu; Justin Bishop; Xiaoli Liu; Hui Sun; Zhongyan Shan; Enhua Wang; Yahong Luo; Xianghong Yang; Jiajun Zhao; Jianling Du; Adel K El-Naggar; Weiping Teng; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2015-01-13       Impact factor: 5.958

3.  Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.

Authors:  Matthew A Nehs; Sushruta Nagarkatti; Carmelo Nucera; Richard A Hodin; Sareh Parangi
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

Review 4.  Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Curr Oncol Rep       Date:  2021-02-13       Impact factor: 5.075

5.  A large nonmetastatic anaplastic thyroid cancer with complete thyroidal confinement.

Authors:  Jeffrey C Xing; Justin A Bishop; Nestoras Mathioudakis; Nishant Agrawal; Ralph P Tufano
Journal:  Case Rep Med       Date:  2011-09-07

6.  Age as a prognostic factor in anaplastic thyroid cancer.

Authors:  Vladan Zivaljevic; Katarina Tausanovic; Ivan Paunovic; Aleksandar Diklic; Nevena Kalezic; Goran Zoric; Vera Sabljak; Berislav Vekic; Rastko Zivic; Jelena Marinkovic; Sandra Sipetic
Journal:  Int J Endocrinol       Date:  2014-06-15       Impact factor: 3.257

7.  Clinico-Pathological Profile of Anaplastic Thyroid Carcinoma in an Endemic Goiter Area.

Authors:  Roma Pradhan; Amit Agarwal; Punita Lal; Niraj Kumari; Manoj Jain; Gyan Chand; Anjali Mishra; Gaurav Agarwal; Ashok K Verma; Saroj K Mishra
Journal:  Indian J Endocrinol Metab       Date:  2018 Nov-Dec

8.  Age Influences the Prognosis of Anaplastic Thyroid Cancer Patients.

Authors:  Na Kong; Qiqi Xu; Ziqin Zhang; Aimin Cui; Shen Tan; Nan Bai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-27       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.